Correlation Study Of Serum TIM-3 With PG,CEA And TAT-2 In The Diagnosis Of Digestive Tract Malignancy

Objective: The clinical value of adjuvant diagnosis of gastrointestinal malignancy(gastric malignancy,colorectal malignancy)and postoperative recurrence of soluble T cell immunoglobulin and mucin domain molecules 3(sTim-3),pepsinogen(PG),carcinoembryonic antigen(CEA),trypsinogen-2(TAT-2),combined with other tumor markers.Methods: Serum sTim-3,TAT-2 and PG were measured in the target population.1.Clinical value of serum sTim-3 and pepsin ogen(PG)for the diagnosis of gastric cancer: Serum levels of sTim-3,PGI and PGII were quantitatively measured in 149 gastric cancer(GC)(123 first gastric and 26 post-gastric patients),81 benign gastric diseases(BGD),and 73 healthy controls.To analyze the combined value of sTim-3and PG for clinical diagnosis of gastric cancer.2.Clinical value of serum sTim-3combined with CEA test for the diagnosis of postoperative recurrence of colorectal cancer(CRC): quantitative detection of serum sTim-3 and CEA levels in 90 postoperative patients(52 patients with postoperative recurrence and 38 patients without postoperative recurrence),21 patients with colorectal benign tumors,and 67 healthy controls.To analyze the clinical diagnostic value of combining sTim-3 and CEA for recurrence after CRC.Among them,90 patients(52 patients with postoperative recurrence and 38 patients without postoperative recurrence)were tested serum TAT-2 to analyze whether the combined test of serum sTim-3 and TAT-2 was better than that of sTim-3 and CEA,and analyzed its clinical value in the evaluation of recurrence after CRC.Results:1 GC(20.41 ± 9.55ng/m L)And BGD(16.50 ± 9.76ng/m L)patients had significantly higher serum sTim-3 levels than the healthy controls(9.22±3.40ng/m L),(P <0.001).The combined test of sTim-3 and PGI / PGII(AUC: 0.9330,sensitivity:86.44%,specificity: 91.78%)had a high diagnostic value for gastric cancer.In addition,in the postoperative patients,the serum sTim-3 level(33.56±4.91ng/m L)was significantly higher in the relapsed group than in the no-recurrence group(11.95±5.16ng/m L);2 The serum sTim-3(15.94±11.24ng/m L)level of patients in the CRC group was significantly higher than that of healthy controls(8.95±3.34ng/m L)and patients with benign colorectal tumors(8.39 ± 2.28ng/m L),(P <0.001),and the serum sTim-3(20.33±13.04ng/m L)level in the CRC group was significantly higher than that in the group without recurrence after CRC group(9.94±2.36ng/m L),(P <0.001).CEA single test after CRC(AUC: 0.7030,sensitivity: 50%,specificity: 85.07%)and the postoperative recurrence group after CRC(AUC: 0.722,sensitivity: 52.78%,specificity: 85.07%)had poor sensitivity,while the combination of serum sTim-3 and CEA for recurrence after CRC(AUC: 0.8850,sensitivity: 80.77%,specificity:85.52%)was better than CEA single test.Further experiments verified that the efficacy of serum sTim-3 and TAT-2(AUC: 0.8940,sensitivity 71.15%,specificity98.51%)was comparable to that of serum sTim-3 and CEA,although the sensitivity was slightly lower,the specificity was significantly higher.Conclusion:1 sTim-3 levels were significantly higher in BGD and GC than in control serum.Furthermore,sTim-3 serum levels can predict postoperative recurrence in patients.The combination of serum PG and sTim-3 could significantly improve the detection sensitivity and specificity of BGD and GC compared with PG alone;Therefore,the combined test of serum PG and sTim-3 can provide a reference value for the diagnosis of BGD and GC.2 The serum level of sTim-3 in patients after CRC was significantly higher than that of blank control group and colorectal benign tumor group.Meanwhile,the serum level of sTim-3 in patients with CRC recurrence was significantly higher than that of those without recurrence after CRC.The efficacy of single CEA test was not optimal,and the combination of sTim-3 in serum could significantly improve the sensitivity and specificity of recurrence after CRC.In addition,the combination of serum sTim-3and TAT-2 for recurrence after CRC was comparable to that of serum sTim-3 and CEA,which could provide new ideas for evaluating the combination of serum tumor markers in adjuvant recurrence examination after CRC.